Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

"VIBRATIONS" - A Study In Smokers Who Are Willing And Motivated To Stop Smoking With The Aid Of Varenicline Which Will Be Prescribed According To Usual Clinical Practice In Germany

Completed

Conditions: Smoking Cessation

Interventions: Drug: Varenicline

First Posted Date: 2010-04-15

Last Posted Date: 2012-03-02

Lead Sponsor: Pfizer

Target Recruit Count: 1177

Registration Number: NCT01104636

Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-02545920
Drug: Placebo

First Posted Date: 2010-04-15

Last Posted Date: 2011-11-16

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT01103726

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

To Explore The Potential For PF-04531083 To Effect The Blood Concentrations Of Simvastatin And Its Main Acid Metabolite Following Co-Administration Of Both Medications

Phase 1

Completed

Conditions: Chronic Pain

Interventions: Drug: PF-04531083
Drug: simvastatin

First Posted Date: 2010-04-15

Last Posted Date: 2010-06-04

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01103739

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa

Phase 3

Terminated

Conditions: Intermittent Preventive Treatment In Pregnancy (IPTp)

Interventions: Drug: Azithromycin plus chloroquine
Drug: sulfadoxine-pyrimethamine

First Posted Date: 2010-04-13

Last Posted Date: 2015-06-16

Lead Sponsor: Pfizer

Target Recruit Count: 2891

Registration Number: NCT01103063

Locations: 🇹🇿
Bugando Medical Centre, Mwanza, Tanzania
🇲🇼
Zomba Central Hospital, Zomba, Malawi
🇹🇿
Nyamagana District Hospital, Mwanza, Tanzania

and more 6 locations

Single Dose Study of PF-04991532 in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders

Interventions: Drug: Placebo
Drug: PF-04991532

First Posted Date: 2010-04-13

Last Posted Date: 2010-08-05

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT01102673

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: Naproxen + PH-797804
Drug: PH-797804
Drug: Placebo
Drug: Naproxen

First Posted Date: 2010-04-13

Last Posted Date: 2014-08-22

Lead Sponsor: Pfizer

Target Recruit Count: 172

Registration Number: NCT01102660

Locations: 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States

CP-690,550 Pharmacokinetics In Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CP-690,550

First Posted Date: 2010-04-12

Last Posted Date: 2011-11-16

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01101919

Locations: 🇨🇳
Pfizer Investigational Site, Beijing, China

Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-04308515 Tablet
Drug: PF-04308515

First Posted Date: 2010-04-12

Last Posted Date: 2011-07-25

Lead Sponsor: Pfizer

Target Recruit Count: 58

Registration Number: NCT01101932

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

Phase 4

Terminated

Conditions: Chronic Pain

Interventions: Drug: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush
Drug: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole

First Posted Date: 2010-04-09

Last Posted Date: 2012-07-13

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT01100437

Locations: 🇺🇸
Lifetree Clinical Research, Salt Lake City, Utah, United States

A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

Phase 3

Completed

Conditions: Macular Edema
Diabetic Mellitus
Retinal Disease

Interventions: Other: sham injection
Drug: pegaptanib sodium

First Posted Date: 2010-04-08

Last Posted Date: 2013-08-23

Lead Sponsor: Pfizer

Target Recruit Count: 243

Registration Number: NCT01100307

Locations: 🇯🇵
Kohnan Hospital, Kobe, Hyogo, Japan
🇯🇵
Nihon University Surugadai Hospital, Chiyoda-ku, Tokyo, Japan
🇯🇵
Shiga University of Medical Science Hospital, Otsu, Shiga, Japan

and more 40 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy